Epilepsy
Learn about CBD and cannabis-based treatments for epilepsy and seizure disorders. Review the science behind Epidiolex, dosage information, and clinical trial results.
Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice. Cannabis is not FDA-approved for most conditions. Always consult a qualified healthcare provider before starting any cannabis-based treatment. Do not use this information to self-diagnose or replace professional medical care.
Overview
Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures affecting approximately 50 million people worldwide. Seizures result from abnormal, excessive electrical activity in the brain and range from brief absence episodes to severe tonic-clonic convulsions. Epilepsy encompasses numerous syndromes including Dravet syndrome, Lennox-Gastaut syndrome, and temporal lobe epilepsy. About one-third of patients have drug-resistant epilepsy, failing to achieve seizure control with two or more anticonvulsant medications. Conventional treatments include valproate, levetiracetam, carbamazepine, and other antiepileptic drugs (AEDs), as well as surgical interventions and vagus nerve stimulation. Epidiolex (pharmaceutical-grade CBD) became the first FDA-approved cannabis-derived medication in 2018, representing a landmark in cannabinoid medicine. This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before beginning any cannabis-based treatment.
How Cannabis Helps
CBD exerts anticonvulsant effects through multiple mechanisms: it modulates intracellular calcium via GPR55 receptor antagonism, reduces neuronal hyperexcitability through TRPV1 channel desensitization, and enhances inhibitory adenosine signaling by blocking equilibrative nucleoside transporter 1 (ENT1). Unlike traditional AEDs that target a single pathway, CBD's multi-target mechanism may explain its efficacy in treatment-resistant epilepsy. CBD does not produce psychoactive effects and has a favorable safety profile compared to many AEDs. THC has shown mixed results for seizures; while some preclinical evidence suggests anticonvulsant properties, it may lower seizure threshold in certain epilepsy types. CBDV (cannabidivarin) is under investigation as an additional anticonvulsant cannabinoid.
Recommended Cannabinoids
CBD
FDA-approved anticonvulsant that reduces seizure frequency through GPR55 antagonism, TRPV1 desensitization, and enhanced adenosine signaling across multiple seizure types.
CBDV
Structurally similar to CBD with independent anticonvulsant properties currently being investigated in clinical trials for focal seizures.
THC (with caution)
Limited evidence of anticonvulsant properties in some seizure types, but may lower seizure threshold in others. Only used under strict medical supervision.
Recommended Consumption Methods
- 1Pharmaceutical-grade CBD oral solution (Epidiolex) as prescribed by neurologist
- 2High-CBD, negligible-THC oral preparations for consistent dosing
- 3CBD oil administered sublingually for more precise dose titration
- 4Avoid inhalation methods due to inconsistent dosing and potential seizure triggers
Dosage Guidance
Epidiolex is dosed at 2.5mg/kg twice daily initially, increasing to a maintenance dose of 5mg/kg twice daily after one week. Maximum recommended dose is 10mg/kg twice daily. For non-pharmaceutical CBD products, dosing is less standardized but typically starts at 2-5mg/kg daily in divided doses. CBD inhibits CYP3A4 and CYP2C19 enzymes, which can significantly increase levels of clobazam and other AEDs, necessitating blood level monitoring and potential dose adjustments of concurrent medications. Liver function tests should be monitored regularly. Never adjust epilepsy medications without neurologist supervision.
Recommended Strains
Strains commonly associated with epilepsy relief, based on reported medical uses.
Research Summary
The pivotal phase III clinical trials (2017-2018) published in the New England Journal of Medicine demonstrated that Epidiolex reduced seizure frequency by 39-44% in Dravet syndrome and 41-44% in Lennox-Gastaut syndrome compared to placebo. These FDA registration trials led to Epidiolex approval in 2018 for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and later tuberous sclerosis complex. A 2021 meta-analysis in Epilepsy & Behavior encompassing 36 studies found that CBD achieved greater than 50% seizure reduction in 43% of treatment-resistant epilepsy patients. Long-term open-label extension studies show sustained efficacy over 3+ years with no evidence of tolerance development.
Side Effects & Risks
- ⚠Elevated liver enzymes (hepatotoxicity), particularly when combined with valproate
- ⚠Somnolence and sedation, especially when combined with clobazam
- ⚠Diarrhea, decreased appetite, and weight changes
- ⚠Drug interactions with multiple AEDs via CYP450 enzyme inhibition
- ⚠Suicidal ideation monitoring required as with all anticonvulsant medications
Frequently Asked Questions
Is CBD FDA-approved for epilepsy?
Yes. Epidiolex (cannabidiol) oral solution was FDA-approved in 2018 for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients one year of age and older. It is the first and currently only FDA-approved cannabis-derived medication.
Can I use over-the-counter CBD for seizures instead of Epidiolex?
Over-the-counter CBD products are not FDA-regulated for epilepsy and may have inconsistent potency, purity, and bioavailability. Epidiolex undergoes rigorous pharmaceutical quality control. If cost is a barrier, discuss options with your neurologist, as patient assistance programs exist.
Will CBD interact with my current seizure medications?
Yes, CBD significantly inhibits CYP3A4 and CYP2C19 liver enzymes, which can increase blood levels of many AEDs, particularly clobazam (levels may double) and valproate. Regular blood level monitoring and dose adjustments are essential when adding CBD to an anticonvulsant regimen.